Replies to post #842 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

Don't be obtuse Dew. I'm not saying do nothing, I am saying slow the burn and be strategic about what you fund non-cosmetically prior to becoming profitable.

Cervical dystonia is the big-cash-burn indication, and running the CD trials expeditiously is probably the right thing to do, for the reason mentioned in #msg-148900313.

The clinical trials in progress (or soon to start) in other indications are comparatively cheap, so deferring or halting them wouldn’t make that much difference in the timing and terms of future capital raises, IMO.